Evidence against a major role for Ca2+ in hypoxia-induced gene expression in human hepatoma cells (Hep3B)

J Physiol. 1999 Jun 15;517 ( Pt 3)(Pt 3):651-7. doi: 10.1111/j.1469-7793.1999.0651s.x.

Abstract

1. The human hepatoma cell line Hep3B is a widely used model for studies of hypoxia-related gene expression. Cytosolic free calcium concentration ([Ca2+]i) has been implicated in cellular oxygen-sensing processes. We investigated whether calcium ions have a significant impact on the production of erythropoietin (EPO) and vascular endothelial growth factor (VEGF). 2. We found that the calcium ionophore ionomycin induced a rapid and sustained increase of [Ca2+]i while thapsigargin, an inhibitor of endoplasmic reticulum calcium ATPase, only caused a 20 % elevation of [Ca2+]i within 10 min after application. However, the calcium content of intracellular stores was considerably reduced by thapsigargin after an incubation period of 24 h. 3. Variations in [Ca2+]o did not result in altered EPO or VEGF secretion rates. Ionomycin decreased EPO production while the lowering of VEGF production was not statistically significant. In the presence of extracellular Ca2+ the membrane permeant calcium chelator BAPTA-AM stimulated the production of EPO (P < 0.05) but not of VEGF while EGTA-AM, a closely related agent, affected neither EPO nor VEGF formation under these conditions. Incubation with thapsigargin resulted in decreased EPO synthesis (P < 0.05) but stimulated VEGF secretion (P < 0.05). 4. In the absence of extracellular calcium, EGTA-AM led to an accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha). This treatment significantly stimulated VEGF synthesis but also decreased EPO secretion (P < 0.05). 5. Our data suggest that the calcium transient and the cytosolic Ca2+ concentration do not play a key role in hypoxia-induced EPO and VEGF production in Hep3B cells.

MeSH terms

  • Blotting, Northern
  • Calcium / physiology*
  • Calcium-Transporting ATPases / antagonists & inhibitors
  • Carcinoma, Hepatocellular
  • Cell Hypoxia / physiology*
  • Chelating Agents / pharmacology
  • Egtazic Acid / analogs & derivatives
  • Egtazic Acid / pharmacology
  • Endothelial Growth Factors / genetics*
  • Enzyme Inhibitors / pharmacology
  • Erythropoietin / genetics*
  • Gene Expression Regulation, Neoplastic* / drug effects
  • Humans
  • Ionomycin / pharmacology
  • Kinetics
  • Liver Neoplasms
  • Lymphokines / genetics*
  • Thapsigargin / pharmacology
  • Tumor Cells, Cultured
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Chelating Agents
  • Endothelial Growth Factors
  • Enzyme Inhibitors
  • Lymphokines
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Erythropoietin
  • 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
  • Egtazic Acid
  • Ionomycin
  • Thapsigargin
  • Calcium-Transporting ATPases
  • Calcium